ELGX News and Press, Endologix Inc. From 10/28/19

Gainers:  Tiffany & Co. (NYSE: TIF ) +31% . Xunlei Limited (NASDAQ: XNET ) +27% . Datasea (NASDAQ: DTSS ) +25% . comScore (NASDAQ: SCOR ) +24% . Fitbit (NYSE: FIT ) +23% . Aquestive Therapeutics (NASDAQ: AQST ) +23% . ChinaNet Online Holdings (NASDAQ: CNET ) +20% . Libbey (...

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2019 after the market close on Wednesday, November 6, 2019. The Company’s management will h...

Endologix, Inc. (ELGX) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants John Onopchenko – Chief Executive Officer Vaseem Mahboob – Chief Financial Officer Matt Thompson – Chief Medical Officer Conference Call Participants ...

The following slide deck was published by Endologix, Inc. in conjunction with their 2019 Q2 earnings Read more ...

Endologix (NASDAQ: ELGX ): Q2 GAAP EPS of -$1.50 misses by $0.43 . More news on: Endologix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced an agreement naming Boston Scientific Corporation (NYSE: BSX) the exclusive distributor for Endologix products in China. The long-term agreement includes distribution rights...

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received Investigational Device Exemption ("IDE") approval from the United States Food and Drug Administration ("FDA") to commence a new pivotal study to evaluate...

Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2019. “We are pleased with our second quarter results, as stronger execution ...

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2019 after the market close on Thursday, August 8, 2019. The Company’s management will host...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...